Patients with higher tumor mRNA levels of both ATR and PrimPol had a lower OS rate than those with KRAS-mutant tumors with lower mRNA levels of both ATR and PrimPol among patients with KRAS-mutant tumors in the LUAD cohort (Fig. 7c). This evidence concerns the gene KRAS and neoplasm.